Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Receptor Protein-Tyrosine Kinases

Known as: Receptor Protein Tyrosine Kinases, Tyrosine Kinase Growth Factor Receptor, Protein-Tyrosine Kinase Receptors 
A class of membrane receptors that contain protein tyrosine kinase activity. This enzymatic activity is integral to the function of the receptor as a… Expand
National Institutes of Health

Related topics

Related topics

50 relations
Cell Differentiation processCell ProliferationEnzyme GeneImatinib mesylate
Expand

Narrower (21)

DRL protein, DrosophilaEPHA3 protein, humanEphA3 ReceptorEphrin Receptor EphB1
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Abstractc-Met is a receptor tyrosine kinase belonging to the MET (MNNG HOS transforming gene) family, and is expressed on the… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Review
2018
Review
2018
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three decades ago, and activating RET… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Review
2018
Review
2018
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
Triple negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer which lacks oestrogen receptors… Expand
Is this relevant?
Review
2018
Review
2018
Role of Microenvironment in Glioma Invasion: What We Learned from In Vitro Models
The invasion properties of glioblastoma hamper a radical surgery and are responsible for its recurrence. Understanding the… Expand
  • figure 2
  • figure 2
  • table 1
  • table 2
  • table 2
Is this relevant?
Review
2017
Review
2017
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
Anaplastic thyroid carcinoma (ATC) is a rare malignancy, accounting for 1–2% of all thyroid cancers. Although rare, ATC accounts… Expand
  • figure 1
  • figure 2
  • table 1
  • table 1
  • figure 3
Is this relevant?
Review
2017
Review
2017
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary tumor in the central nervous system. One of the… Expand
  • figure 1
  • table 1
  • table 2
  • table 2
  • table 3
Is this relevant?
Review
2017
Review
2017
New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management
Pharmacological and cellular treatment of cancer is changing dramatically with benefits for patient outcome and comfort, but also… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Review
2017
Review
2017
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
&NA; The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of cancers, including NSCLC. In… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2017
Review
2017
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly upregulated in cancers such as in non… Expand
  • figure 1
Is this relevant?
Review
2017
Review
2017
Understanding and targeting resistance mechanisms in NSCLC
The expanding spectrum of both established and candidate oncogenic driver mutations identified in non-small-cell lung cancer… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE